Nivolumab May Improve Long-term Complete Response Rate in Subset of Patients With mCRC

Share this content:
Researchers treated 74 patients with dMMR/MSI-H mCRC with nivolumab 3 mg/kg every 2 weeks.
Researchers treated 74 patients with dMMR/MSI-H mCRC with nivolumab 3 mg/kg every 2 weeks.
The following article features coverage from the 2018 Gastrointestinal Cancers Symposium. Click here to read more of Cancer Therapy Advisor's conference coverage.

Long-term data from an ongoing study showed that nivolumab prolongs overall survival (OS) and continues to maintain clinically meaningful durable responses among patients with DNA mismatch repair–deficient/microsatellite instability–high (dMMR/MSI-H) metastatic colorectal cancer (mCRC), according to research being presented at the 2018 Gastrointestinal Cancers Symposium in California.1

For the open-label, phase 2 CheckMate-142 trial (ClinicalTrials.gov Identifier: NCT02060188), researchers treated 74 patients with dMMR/MSI-H mCRC with nivolumab 3 mg/kg every 2 weeks. Eligible patients had progressed or were intolerant of at least 1 previous line of treatment, including a fluoropyrimidine, oxaliplatin, and irinotecan. Results from a previous follow-up showed that the overall response rate (ORR) was 32% and the disease control rate was 64% among patients treated with nivolumab.

The median follow-up of the current study was 21 months. ORR was 34%, and the complete response (CR) rate improved from 3% to 9%. Patients treated with 2 or fewer chemotherapy regimens had numerically higher responses compared with patients who were previously treated with fluoropyrimidine, oxaliplatin, and irinotecan.

Grade 3 to 4 treatment-related adverse events (TRAEs) were observed in 20% of patients; 10% of patients who received 2 or fewer treatment lines reported TRAEs vs 25% of patients who received chemotherapy with fluoropyrimidine, oxaliplatin, and irinotecan.

Read more of Cancer Therapy Advisor's coverage of the 2018 Gastrointestinal Cancers Symposium by visiting the conference page.

Reference

  1. Overman MJ, Bergamo F, McDermott RS, et al. Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): long-term survival according to prior line of treatment from CheckMate-142. Oral presentation at: 2018 Gastrointestinal Cancers Symposium; January 18-20, 2018; San Francisco, CA.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs